{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:04:54Z","timestamp":1790802294468,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117020","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:30:14Z","timestamp":1788503414000},"page":"117020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association of immune and proliferation gene signatures and stromal tumor-infiltrating lymphocytes with clinical outcomes in patients with stage I triple-negative breast cancer"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-0228","authenticated-orcid":false,"given":"Paolo","family":"Tarantino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Par\u00e9 Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7974-3346","authenticated-orcid":false,"given":"Esther","family":"Sanfeliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8695-4424","authenticated-orcid":false,"given":"Beyza","family":"Koca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5979-4883","authenticated-orcid":false,"given":"Marta","family":"Oll\u00e9-Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-0236","authenticated-orcid":false,"given":"Olga","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashka","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-5413","authenticated-orcid":false,"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fara","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Villagrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-167X","authenticated-orcid":false,"given":"Nabihah","family":"Tayob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117020_bib1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117020_bib2","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","article-title":"Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer","volume":"24","author":"Haffty","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117020_bib3","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.117020_bib4","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1002\/cncr.27581","article-title":"Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.117020_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117020_bib6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117020_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117020_bib8","article-title":"Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study","volume":"40","author":"Acs","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ejca.2026.117020_bib9","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer Version 4.2025."},{"key":"10.1016\/j.ejca.2026.117020_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117020_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-26-520666","article-title":"Stage I triple-negative breast cancer: moving from one-size-fits-all to a personalized approach","volume":"46","author":"Idossa","year":"2026","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejca.2026.117020_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41523-024-00634-6","article-title":"Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer","volume":"10","author":"Tarantino","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejca.2026.117020_bib13","first-page":"JCO2101536","article-title":"Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)Adjuvant systemic therapy","author":"de Jong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117020_bib14","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.117020_bib15","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117020_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41523-021-00362-1","article-title":"Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer","volume":"8","author":"Loi","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejca.2026.117020_bib17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117020_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13058-022-01552-w","article-title":"Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial","volume":"24","author":"Kolberg-Liedtke","year":"2022","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2026.117020_bib19","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdz395","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","volume":"30","author":"Park","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117020_bib20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jamaoncol.2024.1917","article-title":"Tumor-infiltrating lymphocytes in patients with stage I triple-negative breast cancer untreated with chemotherapy","volume":"10","author":"Geurts","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.117020_bib21","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117020_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105043","article-title":"A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies","volume":"102","author":"Conte","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejca.2026.117020_bib23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2024.10.012","article-title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy","volume":"36","author":"Martin","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117020_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117020_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejca.2026.117020_bib26","article-title":"Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer","author":"Stecklein","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.117020_bib27","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP Version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:32:35Z","timestamp":1790800355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"alternative-id":["S0959804926008014"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of immune and proliferation gene signatures and stromal tumor-infiltrating lymphocytes with clinical outcomes in patients with stage I triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117020"}}